Public Health Service Act: a Professional Guide to Healthcare Compliance

The PHS Act is the authorizing statute for the nation's most consequential public health agencies. The National Institutes of Health (NIH) derives its research mandate and grant-making authority directly from this law, enabling it to fund biomedical research across universities, hospitals, and private institutions. The Centers for Disease Control and Prevention (CDC) relies on PHS Act provisions to conduct disease surveillance, issue health guidance, and coordinate interstate outbreak response. The Health Resources and Services Administration (HRSA) administers the 340B Drug Pricing Program and other safety-net initiatives under direct PHS Act authority. Entities that receive federal funding through any of these agencies, or that operate programs subject to their oversight, carry compliance obligations that cannot be managed without legal counsel familiar with federal public health mandates.

Section 319 of the PHS Act grants the Secretary of Health and Human Services (HHS) authority to declare a Public Health Emergency when a disease or disorder presents a significant threat to the population. This declaration activates emergency appropriations, expedited regulatory approvals, liability protections under the PREP Act, and targeted waivers of Medicare and Medicaid requirements. The COVID-19 response demonstrated the breadth of this mechanism, as the Section 319 declaration underpinned vaccine deployment, telehealth expansion, and emergency use authorizations. Regulated entities operating under or alongside emergency declarations should retain counsel experienced in healthcare laws to navigate the intersection of administrative flexibility and heightened compliance risk.

The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the Affordable Care Act in 2010, amended Section 351 to create an abbreviated approval pathway under Section 351(k) for biosimilar and interchangeable biological products. A reference biologic approved under the standard BLA pathway receives 12 years of data exclusivity, during which no biosimilar application may rely on the innovator's clinical data. To obtain an interchangeable designation, an applicant must demonstrate that the product produces the same clinical result as the reference product in any given patient. The BPCIA also established the patent dance, a structured information exchange between biosimilar applicants and reference product sponsors intended to resolve intellectual property disputes before market entry. The FDA's Purple Book database catalogues all licensed biologics and their applicable exclusivity determinations, serving as an indispensable resource in biotech patent strategy and bio-intellectual property litigation.

Covered entity eligibility is defined by statute and confirmed through annual HRSA registration. To maintain program participation, covered entities must observe two foundational prohibitions: the duplicate discount prohibition, which bars simultaneous receipt of a 340B discount and a Medicaid rebate on the same drug unit, and the diversion prohibition, which prevents transfer of discounted drugs to individuals outside the covered entity's patient population as defined by HRSA guidance. Violations of either rule can result in program termination and repayment liability. HRSA conducts audits of both covered entities and manufacturers, and findings of knowing and intentional overcharging carry civil monetary penalties of up to $5,000 per violation. The Supreme Court's 2022 ruling in Novartis Pharmaceuticals Corp. .. HHS affirmed HRSA's authority to enforce manufacturer pricing obligations under the program. Entities navigating 340B audit exposure should engage counsel with experience in pharmaceutical regulatory compliance and regulatory compliance.

Section 2711 of the PHS Act, as amended by the ACA, prohibits group health plans and health insurance issuers from imposing lifetime or annual dollar limits on Essential Health Benefits (EHBs). Before this provision took effect, insurers routinely capped coverage at defined lifetime maximums, exposing patients with catastrophic or chronic conditions to uncapped out-of-pocket liability. EHBs, defined under Section 1302 of the ACA, include ambulatory care, emergency services, hospitalization, maternity care, mental health and substance use disorder services, prescription drugs, and rehabilitative services. Any plan offering coverage after the ACA's effective date that imposes prohibited limits is subject to enforcement by the Department of Labor, HHS, and state insurance regulators. Attorneys handling insurance law and insurance regulations disputes should note that Section 2711 claims arise frequently in benefit denial litigation and plan document review. Additional patient protection provisions, including Section 2704's preexisting condition exclusion prohibition, Section 2712's restriction on coverage rescissions, and Section 2719's internal and external appeals mandate, form an interconnected compliance framework that insurers, plan sponsors, and their counsel must navigate with precision. Organizations operating at the intersection of duty of disclosure in insurance obligations and federal coverage mandates, as well as those managing digital health laws and regulations compliance, will encounter PHS Act requirements at multiple points in their regulatory lifecycle.

The Public Health Service Act is not a static text. It continues to evolve through agency rulemaking, judicial interpretation, and congressional amendment. Whether your organization faces a 340B audit, a biosimilar patent dispute, a Section 2711 coverage challenge, or a Public Health Emergency declaration, experienced legal representation grounded in federal public health law is the most reliable foundation for managing regulatory risk.